Esomeprazole (magnesium salt)

Modify Date: 2024-01-31 21:37:34

Esomeprazole (magnesium salt) structure	Common Name	Esomeprazole (magnesium salt)
	CAS Number	1198768-91-0	Molecular Weight	369.72
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₇H₁₉MgN₃O₃S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Esomeprazole (magnesium salt)

Esomeprazole magnesium salt is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells.IC50 value:Target: proton pumpEsomeprazole magnesium salt is a proton pump inhibitor and gastric antisecretory agent indicated for the short-term treatment of gastroesophageal reflux disease in patients with a history of erosive esophagitis.

Name	EsoMeprazole (MagnesiuM salt)

Description	Esomeprazole magnesium salt is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells.IC50 value:Target: proton pumpEsomeprazole magnesium salt is a proton pump inhibitor and gastric antisecretory agent indicated for the short-term treatment of gastroesophageal reflux disease in patients with a history of erosive esophagitis.
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump Research Areas >> Others
References	[1]. Sandstrom M, et al. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. Clin Ther. 2012 Aug;34(8):1828-38. [2]. Johnson TJ, Hedge DD. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. [3]. Thomas C Kupiec, Vasileios Aloumanis, Michel Ben, et al. Physical and Chemical Stability of Esomeprazole Sodium Solutions. Ann Pharmacother. September 2008 ,42 ( 9 ):1247-1251. [4]. Esomeprazole

Description

Related Catalog

Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump

Research Areas >> Others

References

[1]. Sandstrom M, et al. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. Clin Ther. 2012 Aug;34(8):1828-38.

[2]. Johnson TJ, Hedge DD. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

[3]. Thomas C Kupiec, Vasileios Aloumanis, Michel Ben, et al. Physical and Chemical Stability of Esomeprazole Sodium Solutions. Ann Pharmacother. September 2008 ,42 ( 9 ):1247-1251.

[4]. Esomeprazole